Fibrinogen is a newly proposed cardiovascular risk factor that can measure both inflammation, which is likely to be involved in cardiovascular disease pathophysiology, and hemostasis. A large fibrinogen decrease was found with the SERM and no change in the HRT group. The same three to six month follow-up study also compared major side effects. Hot flashes were somewhat increased in the SERM group and decreased in the HRT group relative to placebo. In another study, the SERM did not significantly stimulate the endometrium, whereas estrogen alone did.
Osteoporosis is an important cause of morbidity in women.
Screening consists of assessment of clinical risk and measurement of bone mineral density. Several treatment options are now available for post menopausal women. Many issues involving prevention and management of osteoporosis remain unresolved. Current National Institutes of Health trials have been designed to answer these questions. The University of Alabama School of Medicine designates this educational activity for a maximum of 1 hour in Category 1 credit towards the AMA Physician's Recognition Award.